Publication at Faculty of Medicine in Hradec Králové |
2012
Abstract
For treating patients with COPD, indacaterol, a novel drug from the group of long-lasting beta2-agonists, was introduced into clinical practice. The article summarizes results of published studies to discuss effectiveness of the drug as subjectively perceived by patients themselves in the sense of affecting dyspnea and overall quality of life.